Details of the Drug

General Information of Drug (ID: DMVM13R)

Drug Name
LJPC-401
Indication
Disease Entry ICD 11 Status REF
Beta thalassemia 3A50.2 Phase 2 [1]
Hemochromatosis 5C64.1Y Phase 2 [2]
Drug Type
Peptide
Cross-matching ID
TTD ID
DXM30Y
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepcidin (HAMP) TTPCG5T HEPC_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Beta thalassemia
ICD Disease Classification 3A50.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Hepcidin (HAMP) DTT HAMP 5.37E-01 0.18 0.47
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03381833) A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health.